Effectiveness of intramuscular naloxone 1,600 μg in addition to titrated intravenous naloxone 100 μg for opioid poisoning: a randomised controlled trial.
| Autor: | Isoardi KZ; Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia.; Faculty of Medicine, University of Queensland, Brisbane, Australia.; Clinical Toxicology Research Group, University of Newcastle, Newcastle, Australia., Harris K; Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia.; Faculty of Medicine, University of Queensland, Brisbane, Australia., Currey E; Pharmacy Unit, Princess Alexandra Hospital, Brisbane, Australia., Buckley NA; Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Isbister GK; Clinical Toxicology Research Group, University of Newcastle, Newcastle, Australia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical toxicology (Philadelphia, Pa.) [Clin Toxicol (Phila)] 2024 Oct; Vol. 62 (10), pp. 643-650. Date of Electronic Publication: 2024 Sep 05. |
| DOI: | 10.1080/15563650.2024.2396447 |
| Abstrakt: | Introduction: Naloxone is an effective antidote, but its short half-life means repeated doses, and infusions are often required. We investigated the effectiveness of adding intramuscular naloxone to titrated intravenous naloxone in opioid overdose in preventing recurrence of respiratory depression. Methods: This double-blinded randomised placebo-controlled trial was conducted in patients with suspected opioid poisoning and respiratory depression (respiratory rate <10 breaths/min or oxygen saturation <93%). Patients were randomised to receive either intramuscular naloxone 1,600 µg or saline placebo. All patients received titrated intravenous naloxone 100 µg and were managed on an opioid poisoning care pathway. The primary outcome was recurrence of respiratory depression within 4 h. Secondary outcomes were the proportion receiving naloxone infusions, number of naloxone boluses administered, reversal of respiratory depression at 10 min, and precipitation of opioid withdrawal (any symptom). Results: Recurrence of respiratory depression within 4 h was less common in 28/69 (41%) patients receiving intramuscular naloxone versus 48/67 (72%) patients receiving placebo (difference 31%, 95% CI: 13-46%; P < 0.001). Fewer naloxone infusions (5/69; 7% versus 25/67; 37%, difference 30%, 95% CI: 15 to 55%; P < 0.001) and fewer naloxone doses were administered (median 2, IQR: 1 to 5, versus median 5, IQR: 2 to 8; P = 0.001) in the intramuscular group. Reversal of respiratory depression at 10 min was similar between groups (51/69; 74% intramuscular naloxone versus 47/67; 70% placebo; P = 0.703). Opioid withdrawal occurred in 35/69 (51%) given intramuscular naloxone compared to 28/67 (42%) in the placebo group (difference 9%; 95% CI: -8 to 27%; P = 0.308). Discussion: The favourable pharmacokinetics of intramuscular naloxone, particularly its longer duration of activity, likely explains the improved effectiveness with lower recurrence of respiratory depression. Conclusion: The addition of intramuscular naloxone 1,600 µg to titrated intravenous naloxone prolonged effective reversal of respiratory depression, with fewer naloxone doses and infusions given, and no significant difference in patients developing withdrawal. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|